Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan ; day:26 ; month:10 ; year:2023 ; pages:1-10
Drugs - real world outcomes ; (26.10.2023), 1-10
- Creator
-
Iwasaki, Kotaro
Wakabayashi, Hiroki
Saiki, Atsuhito
Ueshiba, Hajime
Murakami, Yu
Matsuzawa, Yasuo
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40801-023-00396-w
- URN
-
urn:nbn:de:101:1-2024011511454132938372
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Iwasaki, Kotaro
- Wakabayashi, Hiroki
- Saiki, Atsuhito
- Ueshiba, Hajime
- Murakami, Yu
- Matsuzawa, Yasuo
- SpringerLink (Online service)
Other Objects (12)
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment
Antifibrotic therapies to control cardiac fibrosis
Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study
Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
Pneumothorax in patients with idiopathic pulmonary fibrosis: a real-world experience
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment
Antifibrotic therapies to control cardiac fibrosis
Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study
Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
Pneumothorax in patients with idiopathic pulmonary fibrosis: a real-world experience
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment
Antifibrotic therapies to control cardiac fibrosis
Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study
Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
Pneumothorax in patients with idiopathic pulmonary fibrosis: a real-world experience
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis